In this phase 2 study, 410 patients with HER2-positive, node-negative, small breast cancer with tumors 3 cm or smaller were treated with weekly paclitaxel and trastuzumab for 12 weeks, followed by trastuzumab alone for 9 more months, to finish a total of 12 months of therapy. Here, ERBB2 is linked to breast carcinoma.